Study of cohort-specific consent and patient control in phase I cancer trials

Journal of Clinical Oncology

Volumn 16, Issue 7, 1998, Pages 2305-2312

  Daugherty, Christopher K ^a   Ratain, Mark J ^b   Minami, Hironobu ^b   Banik, Donald M ^b   Vogelzang, Nicholas J ^b   Stadler, Walter M ^b   Siegler, Mark ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NAVELBINE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG SCREENING; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; INFORMED CONSENT; INTERMETHOD COMPARISON; INTERVIEW; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEDICAL ETHICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031832108     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.7.2305     Document Type: Article

References (38)

1. United States Food and Drug Administration: General Considerations for the Clinical Evaluation of New Drugs. Washington, DC, United States Government Printing Office, Pub no 77-3040, 1977
2. Levine RJ: Ethics and the Regulation of Clinical Research (ed 2). Baltimore, MD, Vurland and Schwarzenburg, 1986
3. Storer B, DeMets D: Current phase I/II designs: Are they adequate? J Clin Res Drug Dev 1:121-130, 1987
4. Gordon NH, Williams JKV: Using toxicity grades and analysis of cancer phase I clinical trials. Stat Med 11:2063-2075, 1992
5. DeVita VT: Principles of cancer management: Chemotherapy, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott, 1997, pp 333-348
6. Fisher B: Clinical trials for the evaluation of cancer therapy. Cancer 54:2609-2617, 1984
7. Ratain MJ, Mick R, Schilsky R, et al: Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst 85:1637-1643, 1993
8. Von Hoff DD, Turner J: Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs 9:115-122, 1991
9. Estey E, Hoth D, Wittes R, et al: Therapuetic responses in phase I trials of antineoplastic agents. Cancer Treat Rep 70:1105-1115, 1986
10. Decoster G, Stein G, Holdener EE: Responses and toxic deaths in phase I clinical trials. Ann Oncol 2:175-181, 1990
11. Smith TL, Lee JJ, Kantarjian HM, et al: Design and results of phase I cancer clinical trials: Three-year experience at M.D. Anderson Cancer Center. J Clin Oncol 14:287-295, 1996
12. Daugherty CK, Ratain MJ, Grochowski E, et al: Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol 13:1062-1072, 1995
13. Lipsett MB: On the nature and ethics of phase I cancer trials. JAMA 248:941-942, 1982
14. Markman M: The ethical dilemma of phase I clinical trials. CA Cancer J Clin 1986 36:367-369, 1986
15. Sass HM: Ethical considerations in phase I clinical trials. Onkologie 13:85-88, 1990
16. Hawkins MJ: Early cancer clinical trials: Safety, numbers, and consent. J Natl Cancer Inst 85:1618-1619, 1993
17. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC, USGPO, pub 78-0012, 1983
18. Faden RR, Beauchamp TL, King NMP: A History and Theory of Informed Consent. New York, NY, Oxford University Press, 1986
19. Schafner KF: Ethical problems in clinical trials. J Med Philos 11:297-315, 1986
20. Baker MT, Taub HA: Readability of informed consent forms for research in a Veterans Administration medical center. JAMA 250:2646-2648, 1983
21. LoVerde ME, Prochazka AV, Byyny RL: Research consent forms: Continued unreadability and increasing length. J Gen Int Med 4:410-412, 1989
22. Kent G: Shared understanding for informed consent: The relevance of psychological research on the provision of information. Soc Sci Med 43:1517-1524, 1996
23. Daugherty CK, Ratain MJ, Siegler M: Ethical issues in the clinical research of cancer, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott, 1996, pp 534-542
24. Tomamichel M, Sessa C, Herzig S, et al: Informed consent for phase I studies: Evaluation of quantity and quality of information provided to patients. Ann Oncol 6:321-323, 1995
25. Daugherty CK, Ratain MJ, Siegler M: Pushing the envelope: Informed consent in phase I cancer trials. Ann Oncol 6:321-323, 1995
26. Bok S: Shading the truth in seeking informed consent for research purposes. Kennedy Inst Ethics J 5:1-17, 1995
27. Freedman B, Fuks A, Weijer C: Demarcating research and treatment: A systematic approach for the analysis of the ethics of clinical research. Clin Res 40:655-660, 1992
28. Itoh K, Sasaki Y, Fujii H, et al: Patients in phase I trials of anticancer agents in Japan: Motivation, comprehension and expectations. Br J Cancer 76:107-113, 1997
29. EORTC Pharmacokinetics and Metabolism Group. Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines. Eur J Cancer Clin Oncol 23:1083-1087, 1987
30. Collins JM, Greishaber CK, Chabner BA: Pharmacologically guided phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst 82:1321-1326, 1990
31. Mick R, Ratain MJ: Model-guided determination of maximum-tolerated dose in phase I clinical trials: Evidence for increased precision. J Natl Cancer Inst 85:217-223, 1993
32. Graham MA, Workman P: The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: Critical evaluation and recommendations for future studies. Ann Oncol 3:339-347, 1992
33. Freedman B: Cohort-specific consent: An honest approach to phase I cancer studies. IRB Rev Human Subjects Res 12:5-7, 1990
34. Cancer Therapy and Evaluation Program: Common toxicity criteria, in NCI Division of Cancer Treatment Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, National Cancer Institute, 1989
35. Engelhardt HT: The Foundations of Bioethics (ed 2). New York, NY, Oxford University Press, 1996
36. Daugherty CK, Ratain MJ, Siegler M, et al: Learning from our patients: One subject's impact on clinical trial research and informed consent. Ann Int Med 126:892-897, 1997
37. Final Report of the President's Advisory Committee on the Human Radiation Experiments. New York, NY, Oxford University Press, 1996
38. Schaeffer MH, Krantz DA, Wichman A, et al: The impact of disease severity on the informed consent process in clinical research. Am J Med 100:261-268, 1996